![Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial - The Lancet Infectious Diseases Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/ff3fcd42-3af8-4f3a-bd21-0978ffae8520/gr1.jpg)
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial - The Lancet Infectious Diseases
Boost spike after throttle closure? Log attached. - JB4tech.com - International Turbo Tuning Discussion
![Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry - ScienceDirect Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1931312823004110-fx1.jpg)
Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry - ScienceDirect
![Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/asset/d5f2c9cf-7564-4323-ad2c-c492b2547a6d/gr1.jpg)
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
![Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy - eBioMedicine Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy - eBioMedicine](https://www.thelancet.com/cms/attachment/2b318701-6e1d-45b8-a61e-79e7d75d5cd0/gr1.jpg)
Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy - eBioMedicine
![Financial Times on X: "Stéphane Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost Financial Times on X: "Stéphane Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost](https://pbs.twimg.com/media/FFcDEVmXsAIPlxj.jpg:large)
Financial Times on X: "Stéphane Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost
![Frontiers | Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months Frontiers | Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months](https://www.frontiersin.org/files/Articles/1152522/fimmu-14-1152522-HTML/image_m/fimmu-14-1152522-g001.jpg)